130 related articles for article (PubMed ID: 38072402)
1. HGF facilitates methylation of MEG3, potentially implicated in vemurafenib resistance in melanoma.
Jia X; Feng H; He S; Chen X; Feng H; Chen M; Hu X
J Gene Med; 2024 Jan; 26(1):e3644. PubMed ID: 38072402
[TBL] [Abstract][Full Text] [Related]
2. The Interplay between HGF/c-met Axis and Nox4 in BRAF Mutated Melanoma.
Beretti F; Farnetani F; Reggiani Bonetti L; Fabbiani L; Zavatti M; Maiorana A; Pellacani G; Maraldi T
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33451139
[TBL] [Abstract][Full Text] [Related]
3. Hypoxia-Driven Mechanism of Vemurafenib Resistance in Melanoma.
Qin Y; Roszik J; Chattopadhyay C; Hashimoto Y; Liu C; Cooper ZA; Wargo JA; Hwu P; Ekmekcioglu S; Grimm EA
Mol Cancer Ther; 2016 Oct; 15(10):2442-2454. PubMed ID: 27458138
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melanoma.
Hwang S; Kim HE; Min M; Raghunathan R; Panova IP; Munshi R; Ryu B
J Invest Dermatol; 2015 Sep; 135(9):2283-2291. PubMed ID: 25910030
[TBL] [Abstract][Full Text] [Related]
5. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
[TBL] [Abstract][Full Text] [Related]
6. Ezrin mediates both HGF/Met autocrine and non-autocrine signaling-induced metastasis in melanoma.
Huang L; Qin Y; Zuo Q; Bhatnagar K; Xiong J; Merlino G; Yu Y
Int J Cancer; 2018 Apr; 142(8):1652-1663. PubMed ID: 29210059
[TBL] [Abstract][Full Text] [Related]
7. HGF/c-MET Signaling in Melanocytes and Melanoma.
Czyz M
Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30513872
[TBL] [Abstract][Full Text] [Related]
8. Quercetin inhibits HGF/c-Met signaling and HGF-stimulated melanoma cell migration and invasion.
Cao HH; Cheng CY; Su T; Fu XQ; Guo H; Li T; Tse AK; Kwan HY; Yu H; Yu ZL
Mol Cancer; 2015 May; 14():103. PubMed ID: 25971889
[TBL] [Abstract][Full Text] [Related]
9. Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma.
Demkova L; Kucerova L
Mol Cancer; 2018 Feb; 17(1):26. PubMed ID: 29455657
[TBL] [Abstract][Full Text] [Related]
10. Co-expression of hepatocyte growth factor and c-Met predicts peritoneal dissemination established by autocrine hepatocyte growth factor/c-Met signaling in gastric cancer.
Toiyama Y; Yasuda H; Saigusa S; Matushita K; Fujikawa H; Tanaka K; Mohri Y; Inoue Y; Goel A; Kusunoki M
Int J Cancer; 2012 Jun; 130(12):2912-21. PubMed ID: 21796631
[TBL] [Abstract][Full Text] [Related]
11. Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment.
Dratkiewicz E; Simiczyjew A; Pietraszek-Gremplewicz K; Mazurkiewicz J; Nowak D
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31877948
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-101-3p suppresses proliferation and migration in hepatocellular carcinoma by targeting the HGF/c-Met pathway.
Liu Y; Tan J; Ou S; Chen J; Chen L
Invest New Drugs; 2020 Feb; 38(1):60-69. PubMed ID: 30929159
[TBL] [Abstract][Full Text] [Related]
13. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.
Huang X; Gan G; Wang X; Xu T; Xie W
Autophagy; 2019 Jul; 15(7):1258-1279. PubMed ID: 30786811
[TBL] [Abstract][Full Text] [Related]
14. Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma.
Topcu-Yilmaz P; Kiratli H; Saglam A; Söylemezoglu F; Hascelik G
Melanoma Res; 2010 Apr; 20(2):126-32. PubMed ID: 20061986
[TBL] [Abstract][Full Text] [Related]
15. MAPK pathway inhibition induces MET and GAB1 levels, priming BRAF mutant melanoma for rescue by hepatocyte growth factor.
Caenepeel S; Cooke K; Wadsworth S; Huang G; Robert L; Moreno BH; Parisi G; Cajulis E; Kendall R; Beltran P; Ribas A; Coxon A; Hughes PE
Oncotarget; 2017 Mar; 8(11):17795-17809. PubMed ID: 28147313
[TBL] [Abstract][Full Text] [Related]
16. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.
Kubo Y; Fukushima S; Inamori Y; Tsuruta M; Egashira S; Yamada-Kanazawa S; Nakahara S; Tokuzumi A; Miyashita A; Aoi J; Kajihara I; Tomita Y; Wakamatsu K; Jinnin M; Ihn H
J Dermatol Sci; 2019 Jan; 93(1):33-40. PubMed ID: 30318169
[TBL] [Abstract][Full Text] [Related]
17. Activated Hgf-Met Signaling Cooperates with Oncogenic BRAF to Drive Primary Cutaneous Melanomas and Angiotropic Lung Metastases in Mice.
Braun AD; Mengoni M; Bonifatius S; Tüting T; Gaffal E
J Invest Dermatol; 2020 Jul; 140(7):1410-1417.e2. PubMed ID: 31972251
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic regulation of the lncRNA MEG3 and its target c-MET in pancreatic neuroendocrine tumors.
Modali SD; Parekh VI; Kebebew E; Agarwal SK
Mol Endocrinol; 2015 Feb; 29(2):224-37. PubMed ID: 25565142
[TBL] [Abstract][Full Text] [Related]
19. Co-overexpression of Met and hepatocyte growth factor promotes systemic metastasis in NCI-H460 non-small cell lung carcinoma cells.
Navab R; Liu J; Seiden-Long I; Shih W; Li M; Bandarchi B; Chen Y; Lau D; Zu YF; Cescon D; Zhu CQ; Organ S; Ibrahimov E; Ohanessian D; Tsao MS
Neoplasia; 2009 Dec; 11(12):1292-300. PubMed ID: 20019837
[TBL] [Abstract][Full Text] [Related]
20. LINC00240 sponges miR-4465 to promote proliferation, migration, and invasion of hepatocellular carcinoma cells via HGF/c-MET signaling pathway.
Bu WJ; Fang Z; Li WL; Wang X; Dong MJ; Tao QY; Zhang L; Xu YQ
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10452-10461. PubMed ID: 33155201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
